Background
- Androgen receptors (AR) are expressed in up to 55% of ERα negative breast cancers overall and p to 35% of TNBC.
- Similarly expressed rates are seen in high grade serous ovarian cancer (HGSOC).
- Development of AR splice variants (AR SV) has been shown to be a mechanism of androgen resistance in breast and prostate cancers and a poor prognostic feature.
- Specifically AR V7 splice variant is found in aggressive phenotypes of castration resistant prostate cancer marked by shorter PFS and OS.